In rotary tablet manufacturing, spiramycin adipate is rarely processed by direct compression because untreated lots of the adipate salt exhibit cohesive flow and poor bulk density, typically below 0.35 g/mL. A pre-mix of spiramycin adipate, lactose monohydrate and microcrystalline cellulose is dry blended in a tumble blender at 12–20 rpm for 10–15 min, while raw material particle size is controlled by oscillating sieving through a 500 µm screen. The binder solution, prepared with hypromellose at 2–3% w/w or povidone K30 at 3–5% w/w of dry granule mass, is metered into a high-shear granulator bowl of 25–600 L at impeller tip speeds between 4–8 m/s and chopper speeds of 1,500–3,000 rpm. The wet massing endpoint is judged by impeller power consumption and hand squeeze consistency; a fluid-bed dryer then reduces granule moisture to 1.5–3.0% w/w with inlet air at 55–65°C. Dried granules are milled through 0.8–1.0 mm screens, blended with crospovidone at 2–5% w/w and magnesium stearate at 0.5–1.0% w/w for 3–5 min, and compressed on a rotary press to hardness of 80–150 N and friability below 0.8% per Ph.Eur. 2.9.7. Disintegration is maintained below 15 min in 0.1 M HCl at 37°C according to Ph.Eur. 2.9.1; over-lubrication above 1.0% w/w magnesium stearate produces a hydrophobic film that retards dissolution and must be avoided. Because spiramycin adipate has a bitter taste, the tablet core is film-coated with an aqueous hypromellose system to 2–4% w/w weight gain; higher coating levels can delay disintegration beyond the compendial limit. In production areas where relative humidity exceeds 60%, direct compression trials show sticking to dust extraction and feed frames; therefore wet granulation or pre-drying of the API to a loss on drying below 2.0% w/w is required.

Dissolution testing for immediate-release spiramycin adipate tablets is developed from USP chapter 711 using apparatus 2 at 50 rpm in 900 mL of 0.1 M HCl or pH 6.8 phosphate buffer at 37°C; the discriminating medium is selected based on the oral absorption window and stability of the macrolide under acid conditions. Content uniformity is tested according to USP chapter 905 with acceptance value not exceeding 15.0; weight variation is monitored in-process at 5–10 min intervals. Process transfer across tablet presses with different turret speeds requires adjustment of pre-compression force and fill cam depth; published data for the specific compressibility of spiramycin adipate granulations are limited, so pilot batches are run before scale-up to confirm ribbon-to-tablet hardness relationships. Residual solvents are controlled per USP chapter 467 or Ph.Eur. 2.4.24 because isopropanol or ethanol may be used in granulation.

What Limits Direct Compression of Spiramycin Adipate in Hard Capsule Filling?

Direct compression of spiramycin adipate into hard capsules is constrained by flowability and dose size. A 3 MIU adult dose corresponds to roughly 667 mg of spiramycin base at a potency of 4,500 IU/mg; with the adipate counterion and excipient overhead, total fill weight frequently exceeds 800 mg, requiring size 0 or size 00 capsules. Untreated API lots commonly show compressibility indices between 25–35% and Hausner ratios above 1.25 when measured according to USP general chapter 1174, placing the material in the passable-to-poor flow range. At volumetric dosator speeds above 30,000 capsules/h, this flow deficit causes fill weight variability and split capsules. Manufacturers therefore apply dry granulation by slugging or roller compaction, which raises bulk density from 0.25–0.35 g/mL to 0.50–0.65 g/mL and reduces the compressibility index to below 20%. The compacted ribbon is milled through 0.8–1.2 mm screens; retained fines above 35% w/w below 100 µm may cause re-aggregation and should be recycled into subsequent compactions.

For capsule blends, disintegrant and glidant levels differ from tablet formulations. Colloidal silicon dioxide is added at 0.1–0.3% w/w to improve flow, and sodium starch glycolate at 2–4% w/w is preferred over crospovidone when dissolution in acid is rate-limiting. Magnesium stearate is limited to 0.5–0.75% w/w and blended for no longer than 3 min; longer mixing reduces capsule dissolution at 30 min by forming a hydrophobic surface film. Powder moisture is dried to 1.5–2.5% w/w before encapsulation because the adipate salt is hygroscopic and higher moisture increases dosator sticking and lactone-ring hydrolysis. Content uniformity is verified using USP chapter 905 with an acceptance value not greater than 15.0. Capsule shells are selected from low-moisture gelatin or HPMC grades; for hygroscopic formulations, HPMC shells with residual moisture below 5.0% w/w reduce cross-linking brittleness over a 24-month shelf life at 25°C/60% RH.

Sachet Granule Reconstitution and Viscosity Build at 25°C

Unit-dose sachet granules for oral suspension are formulated as a dry blend that is reconstituted with 50–100 mL water at 25°C before administration. The base granulate contains spiramycin adipate, sucrose or sorbitol, and a binder such as povidone or hypromellose; it is dried to 1.0–2.0% w/w moisture and filled into aluminium-foil laminate sachets to exclude oxygen and moisture. The suspending system is critical: xanthan gum at 0.2–0.5% w/v provides pseudoplastic viscosity, while microcrystalline cellulose/sodium carboxymethylcellulose at 0.5–1.0% w/v contributes yield stress and prevents hard settling. After reconstitution, the suspension is shaken for 15–30 s and allowed to stand for 5 min; viscosity measured on a Brookfield RV viscometer with spindle 2 at 50 rpm is controlled between 100–300 mPa·s. Sedimentation volume after 24 h is maintained above 0.90; if the ratio falls below this value, redispersibility and dose uniformity are no longer assured. A citrate buffer system adjusts the final pH to 5.5–7.0 because the macrolide lactone ring is susceptible to hydrolysis outside this range during the in-use period; sodium benzoate or potassium sorbate at 0.05–0.15% w/v may be included when the reconstituted suspension is stored for up to 7 days at 2–8°C. Dissolution testing of the dried granules uses USP chapter 711 apparatus 2 at 75 rpm in 900 mL water or pH 6.8 phosphate buffer at 37°C; sampling at 15 min, 30 min, 45 min, and 60 min characterizes release before the first dose is omitted from the suspension.

Process failures in sachet production are concentrated at the filling machine where electrostatic charges on dry granules cause weight variation if the fill target is below 1.0 g. Humidity control below 35% RH and the use of dedusted granulate with fines below 150 µm minimized are common control measures to prevent segregation during hopper discharge. The sachet seal integrity is tested by vacuum leak method; any pinhole above 15 µm equivalent leak diameter allows moisture ingress and should be rejected. Stability tests are conducted at 40°C/75% RH for 6 months in aluminium-foil laminate; the product is considered acceptable if dissolution recovery at 60 min remains above the registered specification without visible caking or colour change.

In lyophilized vial manufacturing, spiramycin adipate is compounded into a sterile solution under aseptic conditions. The API is dissolved in Water for Injection; batch records commonly target a fill volume of 2–5 mL per vial with a drug concentration justified by the marketed dose. The bulk solution is prefiltered through a 0.45 µm membrane and then sterilized by passage through a 0.22 µm membrane rated for bacterial retention according to ASTM F838-20. The filtered solution is filled into depyrogenated Type I glass vials inside an ISO 14644-1 Class 5 working zone with unidirectional airflow at 0.30–0.50 m/s; depyrogenation is performed in a hot-air tunnel at 250°C for not less than 60 min or a validated equivalent. Stoppers are steam sterilized and dried before use. The filled vials are partially stoppered and transferred to a lyophilizer where the shelf temperature is ramped to −45°C over 2–3 h, held for 3–5 h, and then primary drying is run at a chamber pressure of 50–150 µbar and shelf temperature of −20°C to 0°C for 24–48 h depending on fill depth. Secondary drying at 25–35°C reduces cake moisture to 0.5–2.0% w/w as measured by Karl Fischer titration. The vials are sealed under vacuum or nitrogen with a residual oxygen headspace below 1.0% v/v when the product is oxygen-sensitive.

Endotoxin control begins with the API and excipients; pre-filtration bulk bioburden is maintained below 10 CFU/100 mL and preferably below 1 CFU/100 mL, while the final endotoxin limit is calculated from the maximum adult dose per body weight using Ph.Eur. 2.6.14 or USP chapter 85. Sterility testing uses membrane filtration according to USP chapter 71 with incubation for 14 days; bacteriostasis and fungistasis validation is required before release. The reconstituted solution contains no preservative, so the in-use storage interval after reconstitution should not exceed 24 h at 2–8°C. Particulate matter is assessed by the light obscuration method of Ph.Eur. 2.9.19; subvisible particles must meet the local pharmacopoeial limits for injectable preparations. Because published data on spiramycin adipate lyophilization collapse temperatures are limited, cycle development uses pilot lyophilizer runs with capacitance manometry and product thermocouple mapping rather than relying on a fixed transfer condition.

When Micronized Spiramycin Adipate Is Dispersed in Aqueous Vehicles for Paediatric Oral Use

Micronization by spiral jet milling at nozzle pressures between 5–8 bar lowers the volume mean diameter of spiramycin adipate to 10–25 µm, which improves wetting and reduces grittiness in paediatric oral vehicles. However, the resulting micronized powder is cohesive and becomes electrostatically charged during handling; it is not loaded directly into a final aqueous vehicle because it forms non-wetted agglomerates. The API is first granulated with hypromellose or povidone at 2–4% w/w, dried below 2.0% w/w moisture, and sieved to 150–300 µm. The dry granulate is then suspended in a vehicle containing sorbitol, glycerol, xanthan gum 0.2–0.4% w/v, and citrate buffer q.s. to pH 5.5–6.5. Homogenization is performed with a high-shear mixer at 1,500–2,500 rpm for 10–20 min, followed by vacuum deaeration under 300–500 mbar to reduce foam and entrapped air. Final viscosity is adjusted to 150–400 mPa·s at 25°C, balancing sedimentation control against pourability from an oral syringe.

Taste masking in paediatric products requires additional process investment because spiramycin adipate has a sharp bitter aftertaste. One production-scale approach is to coat the granulated API with a polymethacrylate or ethylcellulose dispersion to a weight gain of 8–15% w/w; the coat must remain intact in the suspension for at least 10 min but dissolve rapidly in gastric pH. Dissolution testing uses USP chapter 711 apparatus 2 at 75 rpm in 900 mL of pH 6.8 phosphate buffer or 0.1 M HCl, with release compared to the adult immediate-release tablet rather than to uncoated API. The accepted sediment ratio after 24 h remains above 0.90, and redispersibility is confirmed by 10 manual inversions of the bottle. Published data for the specific permeability of spiramycin adipate through taste-masking polymer coats are limited; therefore pilot dissolution comparison and blinded palatability panel evaluation are used during transfer between manufacturing sites.

Thermal Liability of the Macrolide Ring Drives Injectable Process Selection

A saturated steam terminal sterilization cycle at 121.1°C for 15 min provides an F0 of 15 min, which achieves a sterility assurance level not exceeding 10⁻⁶ for thermostable parenteral products; such conditions are standard for heat-stable small-molecule solutions. Spiramycin adipate, however, contains a 16-membered lactone ring that is susceptible to hydrolytic opening when exposed to high temperature in aqueous solution. Published production-scale degradation kinetics for spiramycin adipate under terminal steam sterilization are limited; as a result, most injectable configurations are manufactured by aseptic filtration rather than by terminal sterilization. In the aseptic route, the API solution is clarified through a 0.45 µm prefilter and sterilized through a 0.22 µm membrane, with filter integrity testing conducted before and after use by bubble point or diffusion flow according to ASTM F838-20. Pre-filtration bioburden is held below 10 CFU/100 mL, and ideally below 1 CFU/100 mL, to maintain the sterility assurance level of the filtered process. Aseptic filling is performed in an ISO 14644-1 Class 5 environment with unidirectional airflow at 0.30–0.50 m/s; process simulations with sterile medium are run to validate no contamination during filling.

If terminal sterilization is nevertheless considered for a heat-sensitive macrolide, a comparative stability study must demonstrate that total related substances do not increase beyond 1.0% after exposure to an F0 of 8 min or more. The glass vial and rubber stopper can withstand autoclaving, but the active substance may degrade; therefore the decision matrix favors aseptic filtration for spiramycin adipate injectable preparations. For a lyophilized product, terminal sterilization is not applied to the filled liquid because the freeze-drying step occurs after filtration and before sealing; the sealed vial contains dry solid with residual moisture between 0.5–2.0% w/w, and sterility is dependent on the aseptic chain rather than post-fill thermal treatment. Analytical release includes bacterial endotoxin per Ph.Eur. 2.6.14, sterility per USP chapter 71, particulate matter per Ph.Eur. 2.9.19, and moisture by Karl Fischer titration; each batch is also tested for subvisible particles after reconstitution with 10 mL Water for Injection.